Press Releases from 2011

14. Dec Evolva obtains patent coverage in Russia on EV-077 for use in complications of diabetes
8. Dec Evolva to receive second milestone payment from Roche
15. Nov EU approves use of Stevia in food and beverages
11. Nov Alexandra Santana Sorensen to leave Evolva
7. Nov Evolva receives clearance to move EV-077 into Phase IIa
12. Sep Evolva announces interim results for first six months of 2011
18. Aug Evolva Coordinated Sale Process To End
15. Aug Evolva secures financing of up to CHF 30 million
3. Aug Renowned Synthetic Biology and Metabolic Engineering Experts Jay Keasling and Douglas Cameron Join Evolva Scientific Advisory Board
25. Jul Positive ex vivo data on EV-077 in diabetics presented at ISTH conference in Kyoto, Japan
15. Jul Evolva completes Phase I studies with EV-077
8. Jul Evolva completes Abunda acquisition
14. Jun Evolva to receive first milestone payment from Roche
18. May Evolva shareholders approve all Board proposals in AGM
17. May Evolva’s major shareholders agree to continue the coordinated sale
2. May Evolva appoints Norbert Bender as Chief Medical Officer
26. Apr Evolva proposes two leading biotech and food ingredient executives to join its Board
5. Apr Evolva to Acquire Abunda Nutrition
28. Mar FDA clears Evolva’s IND for EV-077 in influenza
22. Mar Evolva to enter the Swiss SPI stock index
17. Mar Evolva announces financial results for 2010
7. Mar BASF and Evolva enter into a collaboration to develop compounds applied to protect crops
24. Feb Evolva announces pre-clinical efficacy data with EV-077 in influenza
13. Jan Evolva enters into collaboration with International Flavors & Fragrances Inc.

Contact Information

Evolva SA
Duggingerstrasse 23
CH-4153 Reinach
Switzerland
Tel: +41 61 485 2000
Fax: +41 61 485 2001
Evolva A/S
Lersoe Parkallé 42-44
DK-2100 Copenhagen OE
Denmark
Tel: +45 35 200 230
Fax: +45 35 200 231
Evolva Biotech Private Limited
401 - 405, 4th Floor
Ticel Bio Park Ltd
Taramani Road, Taramani
Chennai 600 113
Tamil Nadu, India
Tel: +91 44 4297 1050
Fax: +91 44 4297 1060
Evolva, Inc. (Evolva USA)
2440 Embarcadero Way
Palo Alto
CA 94303
USA
Tel: +1 650 856 2436
Fax: +1 650 856 7950

General Enquiries: info@evolva.com • Business Enquiries: busdev@evolva.com • India Enquiries: info_india@evolva.com